Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients

NCT05669833 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

63

Enrollment

OTHER

Sponsor class

Conditions

Psoriatic Arthritis

Interventions

DRUG: Guselkumab
DRUG: Golimumab

Sponsor

University of Pennsylvania

Collaborators

[object Object]